Search results
Showing 1 to 50 of 8903 results
Following the government’s 10 Year Health Plan for England, we're strengthening our role in getting the best healthtech, including digital tools, diagnostics and medical devices, to patients.
Faster, fairer access to HealthTech under new national programme
People across England and Wales are set to receive faster, fairer access to innovative HealthTech under the new National HealthTech Access Programme (NHAP).
With around 2 million healthtech products registered for UK use, differentiating your innovation from the competition is vital. A NICE recommendation helps you cut through the noise, demonstrate your product’s value and smooth your path to market.
Home What NICE does Our guidance About HealthTech guidance NICE: backing the healthtech that changes lives {"@context":"http://schema.org","@ty
Our resource planner tool to help you plan for and implement NICE guidance.
Simple home test prevents thousands of unnecessary bowel cancer referrals
A simple home test is sparing thousands of people from unnecessary hospital investigations for bowel cancer, while helping them get faster answers about whether they have the disease – with new data showing the impact of NICE's recommendation to use the test.
Membership details, terms of reference, future meeting dates and past meeting minutes for our diagnostics advisory committee.
NICE says paperclip-sized sensor could help thousands monitor heart condition from home
A wireless sensor the size of a paperclip could transform care for people living with chronic heart failure, enabling them to monitor their condition daily from home and catch warning signs before they become emergencies, NICE has said.
Pulmonary artery pressure technologies for remote monitoring of chronic heart failure (HTG769)
Evidence-based recommendation on the routine use of pulmonary artery pressure technologies for remote monitoring of chronic heart failure.
Technology appraisal and highly specialised technologies appeals
Learn about the NICE Technology Appraisal and Highly Specialised Technologies appeals process, including how decisions are made, the criteria for appeals, and the role of the appeal panel in ensuring fair and transparent evaluations of health technologies.
How to use NICE guidance to reduce health inequalities in people experiencing cardiovascular disease (CVD).
Help make a difference on behalf of the people most affected by our recommendations on our voluntary and community sector forum.
Evidence-based recommendations on nivolumab (Opdivo) with chemotherapy for neoadjuvant treatment then alone for adjuvant treatment of resectable non-small-cell lung cancer in adults.
Targeted-release budesonide for treating primary IgA nephropathy (TA1128)
Evidence-based recommendations on targeted-release budesonide (Kinpeygo) for treating primary immunoglobulin A (IgA) nephropathy in adults.
Health inequalities are differences in health across the population, and between different groups in society, that are systematic, unfair and avoidable.
Health inequalities can be experienced by people grouped by a range of different factors.
How to use NICE guidance to reduce health inequalities during and after pregnancy.
Membership details, terms of reference, future meeting dates and past meeting minutes for our 4 technology appraisal committees.
Digital technologies to support self-management of COPD: early value assessment (HTG736)
Early value assessment (EVA) guidance on digital technologies to support self-management of COPD.
Home {"@context":"http://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"item":{"@id":"/","name":"Home"}}]}
Subscribe to NICE newsletters and alerts for the latest healthcare guidance, clinical updates, and evidence-based resources across health and social care.
Our recommendations on the use of highly specialised technologies are made by an independent advisory committee
Our recommendations on the use of highly specialised technologies are made by an independent advisory committee
Advises NICE on the formulation of its guidance on the safety and efficacy of interventional procedures.
Home News Podcasts The asthma guideline – one year on Podcasts 29 January 2026 Listen About this episode Developed collaboratively by the
Membership details, terms of reference, future meeting dates and past meeting minutes for our 4 technology appraisal committees.
Reviewing 2025: Producing faster rigorous guidance to make an impact on patients' lives
Home News Podcasts Reviewing 2025: Producing faster rigorous guidance to make an impact on patients' lives Podcasts 17 December 2025 Listen
Getting medicines to NHS patients faster with aligned decisions with the MHRA
Home News Podcasts Getting medicines to NHS patients faster with aligned decisions with the MHRA Podcasts 12 November 2025 Listen About this
Home Get involved Our committees NICE committee meetings...
Home Get involved Our committees NICE committee meetings...
Membership details, terms of reference, future meeting dates and past meeting minutes for our interventional procedures advisory committee.
Membership details, terms of reference, future meeting dates and past meeting minutes for our interventional procedures advisory committee.
Outside interests of the NICE board
Home Freedom of information...
NICE transparency of spend
Evidence-based recommendations on natalizumab originator (Tysabri) and biosimilar (Tyruko) for treating highly active relapsing–remitting multiple sclerosis after disease-modifying therapy in adults.
We offer a dedicated training opportunity towards achieving competency in either Faculty of Public Health Specialty Training curriculum outcomes.
We offer a dedicated training opportunity towards achieving competency in either Faculty of Public Health Specialty Training curriculum outcomes.
Training and development opportunities at NICE
Training and development opportunities at NICE
NICE is unable to make a recommendation on sirolimus (Hyftor) for treating facial angiofibroma caused by tuberous sclerosis complex in people 6 years and over. This is because Plusultra pharma did not provide an adequate evidence submission for committee decision-making.
Show all sections
Sections for TA972
NICE is unable to make a recommendation on concizumab (Alhemo) for treating haemophilia A or B in people 12 years and over with factor inhibitors. This is because the company did not provide an evidence submission.
Show all sections
Sections for TA1124
NICE is unable to make a recommendation on pembrolizumab (Keytruda) with pemetrexed and platinum-based chemotherapy for untreated unresectable advanced malignant pleural mesothelioma in adults. This is because Merck Sharpe & Dohme will not be proceeding with the evidence submission for the appraisal.
Show all sections
Sections for TA1125
Home What NICE does Our guidance About interventional procedures guidance {"@context":"http://schema.org","@type":"BreadcrumbList","itemListElem
Home {"@context":"http://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"item":{"@id":"/","name":"Home"}}]}
Keeping you up-to-date with our worldwide collaborations, opportunities and developments - the NICE International newsletter
Home What NICE does Our guidance About interventional procedures guidance {"@context":"http://schema.org","@type":"BreadcrumbList","itemListElem
Home What NICE does Our guidance Prioritising our guidance topics Our prioritisation decisions...
Use this form to register your interest for a place on the HTA training programme debrief session.
Use this form to register your interest for a place on the HTA training programme debrief session.